Clinical trial NCT02489006: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Official title: A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Ovarian Cancer
Fallopian Tube Cancer
Neoadjuvant Treatment
Debulking Surgical Procedures
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2015-07-02
Enrollment: 71
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer.

Detailed description: Olaparib belongs to a class of anti-cancer agents known as poly ADP-ribose polymerase (PARP) inhibitors. Olaparib is a new type of drug for ovarian cancer. Laboratory tests show that it may help slow the growth of ovarian cancer.

Olaparib works by blocking the PARP protein. PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA, molecules that contain important instructions for the development of cells). Many cancers are thought to develop from damaged DNA. Research has shown that PARP inhibitors stop the PARP protein from working, and that sometimes that can cause cancer cells to stop growing or die.

Eligibility criteria: Inclusion Criteria:

* Histologically proven recurrent high grade serous ovarian/primary peritoneal or fallopian tube cancer.
* Patients must have disease amenable to pre-operative biopsy.
* Patients must have disease deemed suitable for surgical debulking.
* Patients must have a progression free interval of at least 6 months prior to registration.
* Patients must have had at least one line of platinum based therapy.
* Patients must have shown platinum sensitivity to their last line of platinum therapy
* Age \>=18 years
* ECOG performance status 0-1 within 7 days of registration
* Life expectancy of greater than 3 months
* Patients must have normal organ and marrow function
* Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.
* Ability to understand and the willingness to sign a written informed consent document.
* Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

* History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib.
* History of allergic reactions attributed to platinum precluding further use.
* Radiation therapy within 4 weeks of registration
* Use of any other systemic, targeted, immunotherapy, chemotherapy, or investigational agents within 4 weeks of registration
* Previously received a PARP inhibitor
* Other malignancy within the last 2 years with exceptions
* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
* Concomitant use of known potent CYP3A4 inhibitors
* Concomitant use of known potent CYP3A4 inducers
* Other anti-cancer therapy including immunotherapy, hormonal therapy, biological therapy, other novel agents or investigational agents
* Persistent toxicities (CTCAE v 4.03 grade \>2) caused by previous cancer therapy, excluding alopecia
* Patients with myelodysplastic syndrome/acute myeloid leukemia
* Patients with brain metastases
* Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
* Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
* Pregnant or breastfeeding women
* Receipt of live attenuated vaccine within 30 days prior to enrollment
* Patients with \> Grade 2 hearing impairment as per CTCAE v 4.03
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Primary outcomes:
measure: Difference in levels of PAR or PARP-1 before and after study treatment
timeFrame: 4-8 weeks
measure: Mutations in BRCA1/2, RAD51B, RAD51C, RAD51D, PPM1D, FANCM, BRIP1, PALB2 and BARD1 in germline tissue compared to tumor tissue
timeFrame: 2.5 years
Secondary outcomes:
measure: Frequency of adverse events, by description and grade
timeFrame: 2.5 years
measure: Response rate to olaparib in the neoadjuvant period
timeFrame: 6 weeks
measure: Duration of progression free survival with olaparib in comparison to platinum based chemotherapy
timeFrame: 2.5 years
measure: Levels of ctDNA compared to levels of CA125
timeFrame: 2.5 years
measure: Gene expression changes in tumour tissue before and after treatment with Olaparib
timeFrame: 2.5 years
measure: Secondary mutation rate in surgical tumour specimens following PARP therapy and at progression
timeFrame: 2.5 years
measure: Changes in blood based biomarkers using ctDNA before, during and after treatment with Olaparib
timeFrame: 2.5 years
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Ottawa
country: Canada
facility: Ottawa Regional Cancer Centre
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
city: Montréal
country: Canada
facility: Centre hospitalier de l'Université de Montréal (CHUM
state: Quebec
city: Montréal
country: Canada
facility: Jewish General Hospital
state: Quebec
city: Grafton
country: New Zealand
facility: Auckland City Hospital
state: Auckland
city: Barcelona
country: Spain
facility: Vall d'Hebron University Hospital
city: London
country: United Kingdom
facility: Royal Marsden Hospital NHS Foundation Trust
city: London
country: United Kingdom
facility: Imperial College Healthcare NHS Trust
Study officials:
affiliation: Princess Margaret Cancer Centre/University Health Network
name: Amit Oza, M.D.
role: PRINCIPAL_INVESTIGATOR
References: